Cerebral Amyloid Angiopathy

How it works

Risks & contraindications

Background

Highlighted claims

• Cerebral amyloid angiopathy is a major cause of intracerebral haemorrhage, cognitive dysfunction, and dementia in older adults. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial
• CAA involves amyloid-beta deposits in leptomeningeal arteries, cortical arterioles, and capillaries. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial
• Dutch-type hereditary CAA is caused by a mutation at codon 693 of the amyloid precursor protein gene on chromosome 21. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial
• About 60% of lobar intracerebral haemorrhages are attributed to CAA. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial
• No curative or disease-slowing treatment currently exists for CAA. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial
• Most CAA cases worldwide are sporadic. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial